Citalopram updated on 07-01-2025

Oro-facial clefts

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18238
R76504		 Laspro, 2024 Oral clefts (ICD 10 codes Q35 or Q36 or Q37) during pregnancy (anytime or not specified) excluded nested case control unexposed (general population or NOS) Adjustment: No Monotherapy: no or not specified 1.28 [1.11;1.47]
excluded (exposition period) 		199/-   11,899/- 12,098 -
ref
S7471
R22308		 Anderson, 2020 Any oral cleft 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.10 [0.62;1.97] -/-   0/- - -
ref
S5884
R14731		 Ban (Controls unexposed, disease free), 2014 Orofacialcleft 1st trimester retrospective cohort (claims database) unexposed, disease free Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.14 [0.36;3.60] -/1,946   438/325,294 - 1,946
ref
S10215
R37418		 De Jonge, 2013 Oral clefts 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: no or not specified 1.40 [0.09;22.89] C 0/35   294/29,482 294 35
ref
S6014
R15496		 Jimenez-Solem (Controls unexposed, NOS), 2012 Oro-facial clefts 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.80 [0.67;4.81] 4/1,606   -/843,797 - 1,606
ref
Total 4 studies 1.23 [0.79;1.94] 294 3,587
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Anderson, 2020Anderson, 2020 1.10[0.62; 1.97]--61%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Ban (Controls unexposed, disease free), 2014Ban, 2014 1 1.14[0.36; 3.60]-1,94615%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate De Jonge, 2013De Jonge, 2013 1.40[0.09; 22.89]294353%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: critical Jimenez-Solem (Controls unexposed, NOS), 2012Jimenez-Solem, 2012 2 1.80[0.67; 4.81]-1,60621%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: critical Total (4 studies) I2 = 0% 1.23[0.79; 1.94]2943,5870.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, disease free; 2: Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.48[0.70; 3.14]-3,5520%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 2 case control studiescase control studies 1.11[0.63; 1.96]294350%NAAnderson, 2020 De Jonge, 2013 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.23[0.79; 1.94]2943,5870%NAAnderson, 2020 Ban (Controls unexposed, disease free), 2014 De Jonge, 2013 Jimenez-Solem (Controls unexposed, NOS), 2012 4 Tags Adjustment   - No  - No 1.40[0.09; 22.89]29435 -NADe Jonge, 2013 1   - Yes  - Yes 1.23[0.78; 1.94]-3,5520%NAAnderson, 2020 Ban (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 3 Monotherapy   - no or not specified  - no or not specified 1.40[0.09; 22.89]29435 -NADe Jonge, 2013 1   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 1.10[0.62; 1.96]-- -NAAnderson, 2020 1   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.48[0.70; 3.14]-3,5520%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 2 All studiesAll studies 1.23[0.79; 1.94]2943,5870%NAAnderson, 2020 Ban (Controls unexposed, disease free), 2014 De Jonge, 2013 Jimenez-Solem (Controls unexposed, NOS), 2012 40.55.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.43.61.7100.000Anderson, 2020Ban (Controls unexposed, disease free), 2014De Jonge, 2013Jimenez-Solem (Controls unexposed, NOS), 2012

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.23[0.79; 1.94]7233,5870%NAAnderson, 2020 Ban (Controls unexposed, disease free), 2014 De Jonge, 2013 Jimenez-Solem (Controls unexposed, NOS), 2012 40.510.01.0